[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fsa4fkpvvkHWbRYqUp2Rp0cHh0nSUXqCh4fZJ9riXGKQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":54,"rows":61},"University of Leeds",[4],202,false,27,10,7796979,13,160,[14,17,19,22,25,27,30,32],{"name":15,"count":16},"Chronic Heart Failure",8,{"name":18,"count":16},"Multiple Myeloma",{"name":20,"count":21},"Rheumatoid Arthritis",7,{"name":23,"count":24},"Acute Myocardial Infarction",6,{"name":26,"count":24},"Cancer",{"name":28,"count":29},"Heart Failure, Systolic",5,{"name":31,"count":29},"Heart Failure",{"name":33,"count":29},"Obesity",[35,40,45,49],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT02406222","Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)","2022-12","Pomalidomide",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT04550104","A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC","2026-03","Olaparib Oral Tablet [Lynparza]",{"nctId":46,"briefTitle":47,"date":43,"intervention":48},"NCT03562169","The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)","Ixazomib, thalidomide, & dexamethasone (ITD) re-induction",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT06240403","Digoxin and Senolysis in Heart Failure and Diabetes Mellitus","2028-08-28","Digoxin 0.125 MG",[55,56,57,58,59,60],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[62,89,107,125,143,218,245,268,286,312,330,348,366,384,454,492,533,556,578,600,628,646,675,693,711,736,754,772,799,817,842,869,887,905,923,955,973,991,1009,1027,1045,1063,1081,1099,1125,1143,1161,1183,1221,1239,1257,1281,1299,1323,1348,1366,1384,1402,1426,1452,1477,1495,1513,1531,1549,1567,1585,1611,1634,1657,1675,1709,1735,1763,1788,1814],{"intervention":48,"totalTrials":63,"cells":64},1,{"EARLY_PHASE1":65,"PHASE1":68,"PHASE2":70,"PHASE3":72,"PHASE4":85,"NA":87},{"trials":66,"activeCount":67},[],0,{"trials":69,"activeCount":67},[],{"trials":71,"activeCount":67},[],{"trials":73,"activeCount":63,"soonestReadout":43},[74],{"nctId":46,"briefTitle":47,"status":75,"phases":76,"primaryCompletion":43,"completion":77,"start":78,"enrollment":79,"conditions":80,"interventions":81},"RECRUITING",[58],"2027-03","2017-03-20",406,[18],[48,82,83,84],"Conventional autologous stem cell transplant","Augmented autologous stem cell transplant","ITD consolidation and ixazomib maintenance vs. No further therapy",{"trials":86,"activeCount":67},[],{"trials":88,"activeCount":67},[],{"intervention":82,"totalTrials":63,"cells":90},{"EARLY_PHASE1":91,"PHASE1":93,"PHASE2":95,"PHASE3":97,"PHASE4":103,"NA":105},{"trials":92,"activeCount":67},[],{"trials":94,"activeCount":67},[],{"trials":96,"activeCount":67},[],{"trials":98,"activeCount":63,"soonestReadout":43},[99],{"nctId":46,"briefTitle":47,"status":75,"phases":100,"primaryCompletion":43,"completion":77,"start":78,"enrollment":79,"conditions":101,"interventions":102},[58],[18],[48,82,83,84],{"trials":104,"activeCount":67},[],{"trials":106,"activeCount":67},[],{"intervention":83,"totalTrials":63,"cells":108},{"EARLY_PHASE1":109,"PHASE1":111,"PHASE2":113,"PHASE3":115,"PHASE4":121,"NA":123},{"trials":110,"activeCount":67},[],{"trials":112,"activeCount":67},[],{"trials":114,"activeCount":67},[],{"trials":116,"activeCount":63,"soonestReadout":43},[117],{"nctId":46,"briefTitle":47,"status":75,"phases":118,"primaryCompletion":43,"completion":77,"start":78,"enrollment":79,"conditions":119,"interventions":120},[58],[18],[48,82,83,84],{"trials":122,"activeCount":67},[],{"trials":124,"activeCount":67},[],{"intervention":84,"totalTrials":63,"cells":126},{"EARLY_PHASE1":127,"PHASE1":129,"PHASE2":131,"PHASE3":133,"PHASE4":139,"NA":141},{"trials":128,"activeCount":67},[],{"trials":130,"activeCount":67},[],{"trials":132,"activeCount":67},[],{"trials":134,"activeCount":63,"soonestReadout":43},[135],{"nctId":46,"briefTitle":47,"status":75,"phases":136,"primaryCompletion":43,"completion":77,"start":78,"enrollment":79,"conditions":137,"interventions":138},[58],[18],[48,82,83,84],{"trials":140,"activeCount":67},[],{"trials":142,"activeCount":67},[],{"intervention":144,"totalTrials":29,"cells":145},"Cyclophosphamide",{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":150,"PHASE3":212,"PHASE4":214,"NA":216},{"trials":147,"activeCount":67},[],{"trials":149,"activeCount":67},[],{"trials":151,"activeCount":63,"soonestReadout":38},[152,163,176,184,197],{"nctId":153,"briefTitle":154,"status":155,"phases":156,"primaryCompletion":157,"completion":157,"start":157,"enrollment":67,"conditions":158,"interventions":160},"NCT03191981","Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma","WITHDRAWN",[56,57],"2017-08-01",[159],"Myeloma Multiple",[144,161,162],"Lenalidomide","Pembrolizumab",{"nctId":164,"briefTitle":165,"status":166,"phases":167,"primaryCompletion":168,"completion":169,"start":170,"enrollment":171,"conditions":172,"interventions":173},"NCT02461888","Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.","COMPLETED",[57],"2022-04","2025-01-19","2015-12",112,[18],[174,144,175],"Ixazomib","Dexamethasone",{"nctId":36,"briefTitle":37,"status":177,"phases":178,"primaryCompletion":38,"completion":179,"start":180,"enrollment":181,"conditions":182,"interventions":183},"ACTIVE_NOT_RECRUITING",[57],"2025-06","2016-03",124,[18],[39,175,144],{"nctId":185,"briefTitle":186,"status":166,"phases":187,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":192,"interventions":194},"NCT06212596","Selinexor, Cyclophosphamide and Prednisone in Myeloma",[57],"2022-10-25","2023-11-14","2018-07-16",66,[193],"Relapsed or Refractory Multiple Myeloma",[195,144,196],"Selinexor","Prednisone",{"nctId":198,"briefTitle":199,"status":200,"phases":201,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":207},"NCT03188172","MUK Nine b: OPTIMUM Treatment Protocol","UNKNOWN",[57],"2025-10-01","2026-05-31","2017-09-28",95,[18],[144,208,161,209,175,210,211],"Bortezomib","Daratumumab","Melphalan","Filgrastim",{"trials":213,"activeCount":67},[],{"trials":215,"activeCount":67},[],{"trials":217,"activeCount":67},[],{"intervention":175,"totalTrials":219,"cells":220},3,{"EARLY_PHASE1":221,"PHASE1":223,"PHASE2":225,"PHASE3":239,"PHASE4":241,"NA":243},{"trials":222,"activeCount":67},[],{"trials":224,"activeCount":67},[],{"trials":226,"activeCount":63,"soonestReadout":38},[227,231,235],{"nctId":164,"briefTitle":165,"status":166,"phases":228,"primaryCompletion":168,"completion":169,"start":170,"enrollment":171,"conditions":229,"interventions":230},[57],[18],[174,144,175],{"nctId":36,"briefTitle":37,"status":177,"phases":232,"primaryCompletion":38,"completion":179,"start":180,"enrollment":181,"conditions":233,"interventions":234},[57],[18],[39,175,144],{"nctId":198,"briefTitle":199,"status":200,"phases":236,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":237,"interventions":238},[57],[18],[144,208,161,209,175,210,211],{"trials":240,"activeCount":67},[],{"trials":242,"activeCount":67},[],{"trials":244,"activeCount":67},[],{"intervention":53,"totalTrials":63,"cells":246},{"EARLY_PHASE1":247,"PHASE1":249,"PHASE2":251,"PHASE3":262,"PHASE4":264,"NA":266},{"trials":248,"activeCount":67},[],{"trials":250,"activeCount":67},[],{"trials":252,"activeCount":63,"soonestReadout":52},[253],{"nctId":50,"briefTitle":51,"status":254,"phases":255,"primaryCompletion":52,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":261},"NOT_YET_RECRUITING",[57],"2029-08-28","2025-09-01",100,[28,260],"Diabetes Mellitus, Type 2",[53],{"trials":263,"activeCount":67},[],{"trials":265,"activeCount":67},[],{"trials":267,"activeCount":67},[],{"intervention":39,"totalTrials":63,"cells":269},{"EARLY_PHASE1":270,"PHASE1":272,"PHASE2":274,"PHASE3":280,"PHASE4":282,"NA":284},{"trials":271,"activeCount":67},[],{"trials":273,"activeCount":67},[],{"trials":275,"activeCount":63,"soonestReadout":38},[276],{"nctId":36,"briefTitle":37,"status":177,"phases":277,"primaryCompletion":38,"completion":179,"start":180,"enrollment":181,"conditions":278,"interventions":279},[57],[18],[39,175,144],{"trials":281,"activeCount":67},[],{"trials":283,"activeCount":67},[],{"trials":285,"activeCount":67},[],{"intervention":44,"totalTrials":63,"cells":287},{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":304,"PHASE3":306,"PHASE4":308,"NA":310},{"trials":289,"activeCount":67},[],{"trials":291,"activeCount":63,"soonestReadout":43},[292],{"nctId":41,"briefTitle":42,"status":75,"phases":293,"primaryCompletion":43,"completion":294,"start":295,"enrollment":296,"conditions":297,"interventions":299},[56],"2028-03","2021-03-17",200,[298],"Non Small Cell Lung Cancer",[44,300,301,302,303],"AZD1390","Ceralasertib","AZD5305","Durvalumab",{"trials":305,"activeCount":67},[],{"trials":307,"activeCount":67},[],{"trials":309,"activeCount":67},[],{"trials":311,"activeCount":67},[],{"intervention":300,"totalTrials":63,"cells":313},{"EARLY_PHASE1":314,"PHASE1":316,"PHASE2":322,"PHASE3":324,"PHASE4":326,"NA":328},{"trials":315,"activeCount":67},[],{"trials":317,"activeCount":63,"soonestReadout":43},[318],{"nctId":41,"briefTitle":42,"status":75,"phases":319,"primaryCompletion":43,"completion":294,"start":295,"enrollment":296,"conditions":320,"interventions":321},[56],[298],[44,300,301,302,303],{"trials":323,"activeCount":67},[],{"trials":325,"activeCount":67},[],{"trials":327,"activeCount":67},[],{"trials":329,"activeCount":67},[],{"intervention":301,"totalTrials":63,"cells":331},{"EARLY_PHASE1":332,"PHASE1":334,"PHASE2":340,"PHASE3":342,"PHASE4":344,"NA":346},{"trials":333,"activeCount":67},[],{"trials":335,"activeCount":63,"soonestReadout":43},[336],{"nctId":41,"briefTitle":42,"status":75,"phases":337,"primaryCompletion":43,"completion":294,"start":295,"enrollment":296,"conditions":338,"interventions":339},[56],[298],[44,300,301,302,303],{"trials":341,"activeCount":67},[],{"trials":343,"activeCount":67},[],{"trials":345,"activeCount":67},[],{"trials":347,"activeCount":67},[],{"intervention":302,"totalTrials":63,"cells":349},{"EARLY_PHASE1":350,"PHASE1":352,"PHASE2":358,"PHASE3":360,"PHASE4":362,"NA":364},{"trials":351,"activeCount":67},[],{"trials":353,"activeCount":63,"soonestReadout":43},[354],{"nctId":41,"briefTitle":42,"status":75,"phases":355,"primaryCompletion":43,"completion":294,"start":295,"enrollment":296,"conditions":356,"interventions":357},[56],[298],[44,300,301,302,303],{"trials":359,"activeCount":67},[],{"trials":361,"activeCount":67},[],{"trials":363,"activeCount":67},[],{"trials":365,"activeCount":67},[],{"intervention":303,"totalTrials":63,"cells":367},{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":376,"PHASE3":378,"PHASE4":380,"NA":382},{"trials":369,"activeCount":67},[],{"trials":371,"activeCount":63,"soonestReadout":43},[372],{"nctId":41,"briefTitle":42,"status":75,"phases":373,"primaryCompletion":43,"completion":294,"start":295,"enrollment":296,"conditions":374,"interventions":375},[56],[298],[44,300,301,302,303],{"trials":377,"activeCount":67},[],{"trials":379,"activeCount":67},[],{"trials":381,"activeCount":67},[],{"trials":383,"activeCount":67},[],{"intervention":385,"totalTrials":29,"cells":386},"Methotrexate",{"EARLY_PHASE1":387,"PHASE1":389,"PHASE2":391,"PHASE3":405,"PHASE4":407,"NA":452},{"trials":388,"activeCount":67},[],{"trials":390,"activeCount":67},[],{"trials":392,"activeCount":67},[393],{"nctId":394,"briefTitle":395,"status":166,"phases":396,"primaryCompletion":397,"completion":397,"start":398,"enrollment":399,"conditions":400,"interventions":402},"NCT04154852","ADalimumab in Persistent Early Oligoarthrits Study (ADEOS)",[57],"2017-01-16","2011-06",22,[401],"Oligoarthritis",[403,385,404],"Adalimumab","Folic Acid",{"trials":406,"activeCount":67},[],{"trials":408,"activeCount":67},[409,422,432,442],{"nctId":410,"briefTitle":411,"status":166,"phases":412,"primaryCompletion":413,"completion":414,"start":415,"enrollment":416,"conditions":417,"interventions":418},"NCT02433184","Very Early Versus Delayed Etanercept in Patients With RA",[59],"2017-08","2019-07","2011-07",120,[20],[419,385,420,421,419,385],"Etanercept","Sulfasalazine","Hydroxychloroquine",{"nctId":423,"briefTitle":424,"status":166,"phases":425,"primaryCompletion":426,"completion":426,"start":427,"enrollment":171,"conditions":428,"interventions":429},"NCT01308255","Infliximab as Induction Therapy in Early Rheumatoid Arthritis (IDEA)",[59],"2011-02","2006-09",[20],[430,431,385],"Infliximab","Methylprednisolone",{"nctId":433,"briefTitle":434,"status":200,"phases":435,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":439,"interventions":440},"NCT03813771","Targeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-naïve Early RA Patients Based on naïve T-cell Stratification",[59],"2023-02","2019-03",106,[20],[441,420,385,421],"Benepali",{"nctId":443,"briefTitle":444,"status":166,"phases":445,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":449,"interventions":450},"NCT04157010","Tocilizumab REMission in Early RA",[59],"2016-03-29","2013-05",20,[20],[451,385],"Tocilizumab",{"trials":453,"activeCount":67},[],{"intervention":419,"totalTrials":219,"cells":455},{"EARLY_PHASE1":456,"PHASE1":458,"PHASE2":460,"PHASE3":474,"PHASE4":476,"NA":490},{"trials":457,"activeCount":67},[],{"trials":459,"activeCount":67},[],{"trials":461,"activeCount":67},[462],{"nctId":463,"briefTitle":464,"status":166,"phases":465,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":469,"interventions":473},"NCT02656082","Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus",[57],"2017-12-31","2016-02-01",25,[470,471,472],"Lupus Erythematosus, Discoid","Lupus Erythematosus, Cutaneous","Lupus Erythematosus, Chronic Cutaneous",[419],{"trials":475,"activeCount":67},[],{"trials":477,"activeCount":67},[478,482],{"nctId":410,"briefTitle":411,"status":166,"phases":479,"primaryCompletion":413,"completion":414,"start":415,"enrollment":416,"conditions":480,"interventions":481},[59],[20],[419,385,420,421,419,385],{"nctId":483,"briefTitle":484,"status":166,"phases":485,"primaryCompletion":486,"completion":486,"start":427,"enrollment":171,"conditions":487,"interventions":489},"NCT01303874","Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE)",[59],"2010-11-05",[20,488],"Inflammatory Arthritis",[419],{"trials":491,"activeCount":67},[],{"intervention":431,"totalTrials":219,"cells":493},{"EARLY_PHASE1":494,"PHASE1":496,"PHASE2":498,"PHASE3":523,"PHASE4":525,"NA":531},{"trials":495,"activeCount":67},[],{"trials":497,"activeCount":67},[],{"trials":499,"activeCount":67},[500,511],{"nctId":501,"briefTitle":502,"status":503,"phases":504,"primaryCompletion":505,"completion":505,"start":506,"enrollment":63,"conditions":507,"interventions":509},"NCT01216631","Seronegative Oligoarthritis of the Knee Study (SOKS)","TERMINATED",[57],"2011-08","2010-09",[508],"Spondylarthropathies",[510,430,430],"methylprednisolone",{"nctId":512,"briefTitle":513,"status":200,"phases":514,"primaryCompletion":515,"completion":515,"start":516,"enrollment":517,"conditions":518,"interventions":520},"NCT03054259","Rituximab Objective Outcome Measures Trial in SLE",[57],"2020-02","2017-09-21",30,[519],"Systemic Lupus Erythematosus Arthritis",[521,431,522],"Rituximab","Normal Saline",{"trials":524,"activeCount":67},[],{"trials":526,"activeCount":67},[527],{"nctId":423,"briefTitle":424,"status":166,"phases":528,"primaryCompletion":426,"completion":426,"start":427,"enrollment":171,"conditions":529,"interventions":530},[59],[20],[430,431,385],{"trials":532,"activeCount":67},[],{"intervention":420,"totalTrials":534,"cells":535},2,{"EARLY_PHASE1":536,"PHASE1":538,"PHASE2":540,"PHASE3":542,"PHASE4":544,"NA":554},{"trials":537,"activeCount":67},[],{"trials":539,"activeCount":67},[],{"trials":541,"activeCount":67},[],{"trials":543,"activeCount":67},[],{"trials":545,"activeCount":67},[546,550],{"nctId":410,"briefTitle":411,"status":166,"phases":547,"primaryCompletion":413,"completion":414,"start":415,"enrollment":416,"conditions":548,"interventions":549},[59],[20],[419,385,420,421,419,385],{"nctId":433,"briefTitle":434,"status":200,"phases":551,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":552,"interventions":553},[59],[20],[441,420,385,421],{"trials":555,"activeCount":67},[],{"intervention":421,"totalTrials":534,"cells":557},{"EARLY_PHASE1":558,"PHASE1":560,"PHASE2":562,"PHASE3":564,"PHASE4":566,"NA":576},{"trials":559,"activeCount":67},[],{"trials":561,"activeCount":67},[],{"trials":563,"activeCount":67},[],{"trials":565,"activeCount":67},[],{"trials":567,"activeCount":67},[568,572],{"nctId":410,"briefTitle":411,"status":166,"phases":569,"primaryCompletion":413,"completion":414,"start":415,"enrollment":416,"conditions":570,"interventions":571},[59],[20],[419,385,420,421,419,385],{"nctId":433,"briefTitle":434,"status":200,"phases":573,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":574,"interventions":575},[59],[20],[441,420,385,421],{"trials":577,"activeCount":67},[],{"intervention":430,"totalTrials":534,"cells":579},{"EARLY_PHASE1":580,"PHASE1":582,"PHASE2":584,"PHASE3":590,"PHASE4":592,"NA":598},{"trials":581,"activeCount":67},[],{"trials":583,"activeCount":67},[],{"trials":585,"activeCount":67},[586],{"nctId":501,"briefTitle":502,"status":503,"phases":587,"primaryCompletion":505,"completion":505,"start":506,"enrollment":63,"conditions":588,"interventions":589},[57],[508],[510,430,430],{"trials":591,"activeCount":67},[],{"trials":593,"activeCount":67},[594],{"nctId":423,"briefTitle":424,"status":166,"phases":595,"primaryCompletion":426,"completion":426,"start":427,"enrollment":171,"conditions":596,"interventions":597},[59],[20],[430,431,385],{"trials":599,"activeCount":67},[],{"intervention":403,"totalTrials":534,"cells":601},{"EARLY_PHASE1":602,"PHASE1":604,"PHASE2":606,"PHASE3":612,"PHASE4":614,"NA":626},{"trials":603,"activeCount":67},[],{"trials":605,"activeCount":67},[],{"trials":607,"activeCount":67},[608],{"nctId":394,"briefTitle":395,"status":166,"phases":609,"primaryCompletion":397,"completion":397,"start":398,"enrollment":399,"conditions":610,"interventions":611},[57],[401],[403,385,404],{"trials":613,"activeCount":67},[],{"trials":615,"activeCount":67},[616],{"nctId":617,"briefTitle":618,"status":166,"phases":619,"primaryCompletion":620,"completion":414,"start":621,"enrollment":622,"conditions":623,"interventions":625},"NCT02056184","Targeted Ultrasound in Rheumatoid Arthritis",[59],"2017-12","2013-12",183,[20,624],"Targeted Ultrasound",[403],{"trials":627,"activeCount":67},[],{"intervention":441,"totalTrials":63,"cells":629},{"EARLY_PHASE1":630,"PHASE1":632,"PHASE2":634,"PHASE3":636,"PHASE4":638,"NA":644},{"trials":631,"activeCount":67},[],{"trials":633,"activeCount":67},[],{"trials":635,"activeCount":67},[],{"trials":637,"activeCount":67},[],{"trials":639,"activeCount":67},[640],{"nctId":433,"briefTitle":434,"status":200,"phases":641,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":642,"interventions":643},[59],[20],[441,420,385,421],{"trials":645,"activeCount":67},[],{"intervention":647,"totalTrials":63,"cells":648},"0.1% bupivacaine",{"EARLY_PHASE1":649,"PHASE1":651,"PHASE2":653,"PHASE3":655,"PHASE4":657,"NA":673},{"trials":650,"activeCount":67},[],{"trials":652,"activeCount":67},[],{"trials":654,"activeCount":67},[],{"trials":656,"activeCount":67},[],{"trials":658,"activeCount":67},[659],{"nctId":660,"briefTitle":661,"status":200,"phases":662,"primaryCompletion":663,"completion":663,"start":664,"enrollment":258,"conditions":665,"interventions":670},"NCT02116842","Minimum Effective Dose (MED) & Epidural Bupivacaine",[59],"2014-05","2012-12",[666,667,668,669],"Pregnancy","Labour","Primigravida Labour","Epidural Block",[647,671,672],"0.075% bupivacaine","40 µg fentanyl",{"trials":674,"activeCount":67},[],{"intervention":671,"totalTrials":63,"cells":676},{"EARLY_PHASE1":677,"PHASE1":679,"PHASE2":681,"PHASE3":683,"PHASE4":685,"NA":691},{"trials":678,"activeCount":67},[],{"trials":680,"activeCount":67},[],{"trials":682,"activeCount":67},[],{"trials":684,"activeCount":67},[],{"trials":686,"activeCount":67},[687],{"nctId":660,"briefTitle":661,"status":200,"phases":688,"primaryCompletion":663,"completion":663,"start":664,"enrollment":258,"conditions":689,"interventions":690},[59],[666,667,668,669],[647,671,672],{"trials":692,"activeCount":67},[],{"intervention":672,"totalTrials":63,"cells":694},{"EARLY_PHASE1":695,"PHASE1":697,"PHASE2":699,"PHASE3":701,"PHASE4":703,"NA":709},{"trials":696,"activeCount":67},[],{"trials":698,"activeCount":67},[],{"trials":700,"activeCount":67},[],{"trials":702,"activeCount":67},[],{"trials":704,"activeCount":67},[705],{"nctId":660,"briefTitle":661,"status":200,"phases":706,"primaryCompletion":663,"completion":663,"start":664,"enrollment":258,"conditions":707,"interventions":708},[59],[666,667,668,669],[647,671,672],{"trials":710,"activeCount":67},[],{"intervention":712,"totalTrials":63,"cells":713},"Liraglutide",{"EARLY_PHASE1":714,"PHASE1":716,"PHASE2":718,"PHASE3":720,"PHASE4":722,"NA":734},{"trials":715,"activeCount":67},[],{"trials":717,"activeCount":67},[],{"trials":719,"activeCount":67},[],{"trials":721,"activeCount":67},[],{"trials":723,"activeCount":67},[724],{"nctId":725,"briefTitle":726,"status":166,"phases":727,"primaryCompletion":728,"completion":728,"start":729,"enrollment":730,"conditions":731,"interventions":732},"NCT04657939","Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes",[59],"2022-10-31","2020-12-01",57,[260],[712,733],"Pioglitazone",{"trials":735,"activeCount":67},[],{"intervention":733,"totalTrials":63,"cells":737},{"EARLY_PHASE1":738,"PHASE1":740,"PHASE2":742,"PHASE3":744,"PHASE4":746,"NA":752},{"trials":739,"activeCount":67},[],{"trials":741,"activeCount":67},[],{"trials":743,"activeCount":67},[],{"trials":745,"activeCount":67},[],{"trials":747,"activeCount":67},[748],{"nctId":725,"briefTitle":726,"status":166,"phases":749,"primaryCompletion":728,"completion":728,"start":729,"enrollment":730,"conditions":750,"interventions":751},[59],[260],[712,733],{"trials":753,"activeCount":67},[],{"intervention":451,"totalTrials":63,"cells":755},{"EARLY_PHASE1":756,"PHASE1":758,"PHASE2":760,"PHASE3":762,"PHASE4":764,"NA":770},{"trials":757,"activeCount":67},[],{"trials":759,"activeCount":67},[],{"trials":761,"activeCount":67},[],{"trials":763,"activeCount":67},[],{"trials":765,"activeCount":67},[766],{"nctId":443,"briefTitle":444,"status":166,"phases":767,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":768,"interventions":769},[59],[20],[451,385],{"trials":771,"activeCount":67},[],{"intervention":773,"totalTrials":63,"cells":774},"Liposomal bupivacaine",{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":781,"PHASE4":795,"NA":797},{"trials":776,"activeCount":67},[],{"trials":778,"activeCount":67},[],{"trials":780,"activeCount":67},[],{"trials":782,"activeCount":67},[783],{"nctId":784,"briefTitle":785,"status":166,"phases":786,"primaryCompletion":787,"completion":788,"start":789,"enrollment":790,"conditions":791,"interventions":793},"NCT03326180","Study of Peri-Articular Anaesthetic for Replacement of the Knee",[58],"2021-02-28","2021-04-21","2018-03-29",533,[792],"Knee Osteoarthritis",[773,794],"Bupivacaine hydrochloride",{"trials":796,"activeCount":67},[],{"trials":798,"activeCount":67},[],{"intervention":794,"totalTrials":63,"cells":800},{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":807,"PHASE4":813,"NA":815},{"trials":802,"activeCount":67},[],{"trials":804,"activeCount":67},[],{"trials":806,"activeCount":67},[],{"trials":808,"activeCount":67},[809],{"nctId":784,"briefTitle":785,"status":166,"phases":810,"primaryCompletion":787,"completion":788,"start":789,"enrollment":790,"conditions":811,"interventions":812},[58],[792],[773,794],{"trials":814,"activeCount":67},[],{"trials":816,"activeCount":67},[],{"intervention":818,"totalTrials":63,"cells":819},"Ondansetron",{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":826,"PHASE4":838,"NA":840},{"trials":821,"activeCount":67},[],{"trials":823,"activeCount":67},[],{"trials":825,"activeCount":67},[],{"trials":827,"activeCount":67},[828],{"nctId":829,"briefTitle":830,"status":166,"phases":831,"primaryCompletion":832,"completion":833,"start":789,"enrollment":834,"conditions":835,"interventions":837},"NCT03555188","TReatment of Irritable Bowel Syndrome With Diarrhoea Using Titrated ONdansetron Trial",[58],"2020-08-03","2020-09-10",80,[836],"IBS - Irritable Bowel Syndrome",[818],{"trials":839,"activeCount":67},[],{"trials":841,"activeCount":67},[],{"intervention":843,"totalTrials":63,"cells":844},"R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm",{"EARLY_PHASE1":845,"PHASE1":847,"PHASE2":849,"PHASE3":851,"PHASE4":865,"NA":867},{"trials":846,"activeCount":67},[],{"trials":848,"activeCount":67},[],{"trials":850,"activeCount":67},[],{"trials":852,"activeCount":67},[853],{"nctId":854,"briefTitle":855,"status":200,"phases":856,"primaryCompletion":857,"completion":857,"start":858,"enrollment":859,"conditions":860,"interventions":861},"NCT03720041","Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma",[58],"2024-12","2020-08-04",740,[18],[843,862,863,864],"R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm","R2: Lenalidomide plus placebo maintenance","R2: Lenalidomide + ixazomib maintenance",{"trials":866,"activeCount":67},[],{"trials":868,"activeCount":67},[],{"intervention":862,"totalTrials":63,"cells":870},{"EARLY_PHASE1":871,"PHASE1":873,"PHASE2":875,"PHASE3":877,"PHASE4":883,"NA":885},{"trials":872,"activeCount":67},[],{"trials":874,"activeCount":67},[],{"trials":876,"activeCount":67},[],{"trials":878,"activeCount":67},[879],{"nctId":854,"briefTitle":855,"status":200,"phases":880,"primaryCompletion":857,"completion":857,"start":858,"enrollment":859,"conditions":881,"interventions":882},[58],[18],[843,862,863,864],{"trials":884,"activeCount":67},[],{"trials":886,"activeCount":67},[],{"intervention":863,"totalTrials":63,"cells":888},{"EARLY_PHASE1":889,"PHASE1":891,"PHASE2":893,"PHASE3":895,"PHASE4":901,"NA":903},{"trials":890,"activeCount":67},[],{"trials":892,"activeCount":67},[],{"trials":894,"activeCount":67},[],{"trials":896,"activeCount":67},[897],{"nctId":854,"briefTitle":855,"status":200,"phases":898,"primaryCompletion":857,"completion":857,"start":858,"enrollment":859,"conditions":899,"interventions":900},[58],[18],[843,862,863,864],{"trials":902,"activeCount":67},[],{"trials":904,"activeCount":67},[],{"intervention":864,"totalTrials":63,"cells":906},{"EARLY_PHASE1":907,"PHASE1":909,"PHASE2":911,"PHASE3":913,"PHASE4":919,"NA":921},{"trials":908,"activeCount":67},[],{"trials":910,"activeCount":67},[],{"trials":912,"activeCount":67},[],{"trials":914,"activeCount":67},[915],{"nctId":854,"briefTitle":855,"status":200,"phases":916,"primaryCompletion":857,"completion":857,"start":858,"enrollment":859,"conditions":917,"interventions":918},[58],[18],[843,862,863,864],{"trials":920,"activeCount":67},[],{"trials":922,"activeCount":67},[],{"intervention":924,"totalTrials":63,"cells":925},"Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen",{"EARLY_PHASE1":926,"PHASE1":928,"PHASE2":930,"PHASE3":932,"PHASE4":951,"NA":953},{"trials":927,"activeCount":67},[],{"trials":929,"activeCount":67},[],{"trials":931,"activeCount":67},[],{"trials":933,"activeCount":67},[934],{"nctId":935,"briefTitle":936,"status":200,"phases":937,"primaryCompletion":938,"completion":38,"start":939,"enrollment":940,"conditions":941,"interventions":942},"NCT01554852","Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients",[58],"2021-12","2010-05",4420,[18],[924,943,944,945,946,947,948,949,950],"Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen","Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen","Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen","Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen","Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen","Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance","Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance","High dose melphalan therapy and autologous stem cell transplant",{"trials":952,"activeCount":67},[],{"trials":954,"activeCount":67},[],{"intervention":943,"totalTrials":63,"cells":956},{"EARLY_PHASE1":957,"PHASE1":959,"PHASE2":961,"PHASE3":963,"PHASE4":969,"NA":971},{"trials":958,"activeCount":67},[],{"trials":960,"activeCount":67},[],{"trials":962,"activeCount":67},[],{"trials":964,"activeCount":67},[965],{"nctId":935,"briefTitle":936,"status":200,"phases":966,"primaryCompletion":938,"completion":38,"start":939,"enrollment":940,"conditions":967,"interventions":968},[58],[18],[924,943,944,945,946,947,948,949,950],{"trials":970,"activeCount":67},[],{"trials":972,"activeCount":67},[],{"intervention":944,"totalTrials":63,"cells":974},{"EARLY_PHASE1":975,"PHASE1":977,"PHASE2":979,"PHASE3":981,"PHASE4":987,"NA":989},{"trials":976,"activeCount":67},[],{"trials":978,"activeCount":67},[],{"trials":980,"activeCount":67},[],{"trials":982,"activeCount":67},[983],{"nctId":935,"briefTitle":936,"status":200,"phases":984,"primaryCompletion":938,"completion":38,"start":939,"enrollment":940,"conditions":985,"interventions":986},[58],[18],[924,943,944,945,946,947,948,949,950],{"trials":988,"activeCount":67},[],{"trials":990,"activeCount":67},[],{"intervention":945,"totalTrials":63,"cells":992},{"EARLY_PHASE1":993,"PHASE1":995,"PHASE2":997,"PHASE3":999,"PHASE4":1005,"NA":1007},{"trials":994,"activeCount":67},[],{"trials":996,"activeCount":67},[],{"trials":998,"activeCount":67},[],{"trials":1000,"activeCount":67},[1001],{"nctId":935,"briefTitle":936,"status":200,"phases":1002,"primaryCompletion":938,"completion":38,"start":939,"enrollment":940,"conditions":1003,"interventions":1004},[58],[18],[924,943,944,945,946,947,948,949,950],{"trials":1006,"activeCount":67},[],{"trials":1008,"activeCount":67},[],{"intervention":946,"totalTrials":63,"cells":1010},{"EARLY_PHASE1":1011,"PHASE1":1013,"PHASE2":1015,"PHASE3":1017,"PHASE4":1023,"NA":1025},{"trials":1012,"activeCount":67},[],{"trials":1014,"activeCount":67},[],{"trials":1016,"activeCount":67},[],{"trials":1018,"activeCount":67},[1019],{"nctId":935,"briefTitle":936,"status":200,"phases":1020,"primaryCompletion":938,"completion":38,"start":939,"enrollment":940,"conditions":1021,"interventions":1022},[58],[18],[924,943,944,945,946,947,948,949,950],{"trials":1024,"activeCount":67},[],{"trials":1026,"activeCount":67},[],{"intervention":947,"totalTrials":63,"cells":1028},{"EARLY_PHASE1":1029,"PHASE1":1031,"PHASE2":1033,"PHASE3":1035,"PHASE4":1041,"NA":1043},{"trials":1030,"activeCount":67},[],{"trials":1032,"activeCount":67},[],{"trials":1034,"activeCount":67},[],{"trials":1036,"activeCount":67},[1037],{"nctId":935,"briefTitle":936,"status":200,"phases":1038,"primaryCompletion":938,"completion":38,"start":939,"enrollment":940,"conditions":1039,"interventions":1040},[58],[18],[924,943,944,945,946,947,948,949,950],{"trials":1042,"activeCount":67},[],{"trials":1044,"activeCount":67},[],{"intervention":948,"totalTrials":63,"cells":1046},{"EARLY_PHASE1":1047,"PHASE1":1049,"PHASE2":1051,"PHASE3":1053,"PHASE4":1059,"NA":1061},{"trials":1048,"activeCount":67},[],{"trials":1050,"activeCount":67},[],{"trials":1052,"activeCount":67},[],{"trials":1054,"activeCount":67},[1055],{"nctId":935,"briefTitle":936,"status":200,"phases":1056,"primaryCompletion":938,"completion":38,"start":939,"enrollment":940,"conditions":1057,"interventions":1058},[58],[18],[924,943,944,945,946,947,948,949,950],{"trials":1060,"activeCount":67},[],{"trials":1062,"activeCount":67},[],{"intervention":949,"totalTrials":63,"cells":1064},{"EARLY_PHASE1":1065,"PHASE1":1067,"PHASE2":1069,"PHASE3":1071,"PHASE4":1077,"NA":1079},{"trials":1066,"activeCount":67},[],{"trials":1068,"activeCount":67},[],{"trials":1070,"activeCount":67},[],{"trials":1072,"activeCount":67},[1073],{"nctId":935,"briefTitle":936,"status":200,"phases":1074,"primaryCompletion":938,"completion":38,"start":939,"enrollment":940,"conditions":1075,"interventions":1076},[58],[18],[924,943,944,945,946,947,948,949,950],{"trials":1078,"activeCount":67},[],{"trials":1080,"activeCount":67},[],{"intervention":950,"totalTrials":63,"cells":1082},{"EARLY_PHASE1":1083,"PHASE1":1085,"PHASE2":1087,"PHASE3":1089,"PHASE4":1095,"NA":1097},{"trials":1084,"activeCount":67},[],{"trials":1086,"activeCount":67},[],{"trials":1088,"activeCount":67},[],{"trials":1090,"activeCount":67},[1091],{"nctId":935,"briefTitle":936,"status":200,"phases":1092,"primaryCompletion":938,"completion":38,"start":939,"enrollment":940,"conditions":1093,"interventions":1094},[58],[18],[924,943,944,945,946,947,948,949,950],{"trials":1096,"activeCount":67},[],{"trials":1098,"activeCount":67},[],{"intervention":1100,"totalTrials":63,"cells":1101},"panitumumab",{"EARLY_PHASE1":1102,"PHASE1":1104,"PHASE2":1106,"PHASE3":1108,"PHASE4":1121,"NA":1123},{"trials":1103,"activeCount":67},[],{"trials":1105,"activeCount":67},[],{"trials":1107,"activeCount":67},[],{"trials":1109,"activeCount":67},[1110],{"nctId":1111,"briefTitle":1112,"status":166,"phases":1113,"start":1114,"enrollment":1115,"conditions":1116,"interventions":1118},"NCT00389870","Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil",[58],"2006-12",1198,[1117],"Colorectal Cancer",[1100,1119,1120],"cyclosporine","irinotecan hydrochloride",{"trials":1122,"activeCount":67},[],{"trials":1124,"activeCount":67},[],{"intervention":1119,"totalTrials":63,"cells":1126},{"EARLY_PHASE1":1127,"PHASE1":1129,"PHASE2":1131,"PHASE3":1133,"PHASE4":1139,"NA":1141},{"trials":1128,"activeCount":67},[],{"trials":1130,"activeCount":67},[],{"trials":1132,"activeCount":67},[],{"trials":1134,"activeCount":67},[1135],{"nctId":1111,"briefTitle":1112,"status":166,"phases":1136,"start":1114,"enrollment":1115,"conditions":1137,"interventions":1138},[58],[1117],[1100,1119,1120],{"trials":1140,"activeCount":67},[],{"trials":1142,"activeCount":67},[],{"intervention":1120,"totalTrials":63,"cells":1144},{"EARLY_PHASE1":1145,"PHASE1":1147,"PHASE2":1149,"PHASE3":1151,"PHASE4":1157,"NA":1159},{"trials":1146,"activeCount":67},[],{"trials":1148,"activeCount":67},[],{"trials":1150,"activeCount":67},[],{"trials":1152,"activeCount":67},[1153],{"nctId":1111,"briefTitle":1112,"status":166,"phases":1154,"start":1114,"enrollment":1115,"conditions":1155,"interventions":1156},[58],[1117],[1100,1119,1120],{"trials":1158,"activeCount":67},[],{"trials":1160,"activeCount":67},[],{"intervention":161,"totalTrials":534,"cells":1162},{"EARLY_PHASE1":1163,"PHASE1":1165,"PHASE2":1167,"PHASE3":1177,"PHASE4":1179,"NA":1181},{"trials":1164,"activeCount":67},[],{"trials":1166,"activeCount":67},[],{"trials":1168,"activeCount":67},[1169,1173],{"nctId":153,"briefTitle":154,"status":155,"phases":1170,"primaryCompletion":157,"completion":157,"start":157,"enrollment":67,"conditions":1171,"interventions":1172},[56,57],[159],[144,161,162],{"nctId":198,"briefTitle":199,"status":200,"phases":1174,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":1175,"interventions":1176},[57],[18],[144,208,161,209,175,210,211],{"trials":1178,"activeCount":67},[],{"trials":1180,"activeCount":67},[],{"trials":1182,"activeCount":67},[],{"intervention":1184,"totalTrials":534,"cells":1185},"Reolysin",{"EARLY_PHASE1":1186,"PHASE1":1188,"PHASE2":1202,"PHASE3":1215,"PHASE4":1217,"NA":1219},{"trials":1187,"activeCount":67},[],{"trials":1189,"activeCount":67},[1190],{"nctId":1191,"briefTitle":1192,"status":200,"phases":1193,"primaryCompletion":1194,"completion":1195,"start":1196,"enrollment":1197,"conditions":1198,"interventions":1199},"NCT03015922","Viral Immunotherapy in Relapsed\u002FRefractory Multiple Myeloma",[56],"2021-09-01","2021-10-01","2017-06-05",4,[18],[1200,1201],"Lenalidomide or Pomalidomide","REOLYSIN",{"trials":1203,"activeCount":67},[1204],{"nctId":1205,"briefTitle":1206,"status":155,"phases":1207,"primaryCompletion":1208,"completion":1208,"start":1209,"enrollment":67,"conditions":1210,"interventions":1213},"NCT03282188","REO13 Melanoma With of Without GM-CSF",[56,57],"2018-07","2017-10",[1211,1212],"Melanoma","Cancer of Skin",[1184,1214],"GM-CSF",{"trials":1216,"activeCount":67},[],{"trials":1218,"activeCount":67},[],{"trials":1220,"activeCount":67},[],{"intervention":521,"totalTrials":63,"cells":1222},{"EARLY_PHASE1":1223,"PHASE1":1225,"PHASE2":1227,"PHASE3":1233,"PHASE4":1235,"NA":1237},{"trials":1224,"activeCount":67},[],{"trials":1226,"activeCount":67},[],{"trials":1228,"activeCount":67},[1229],{"nctId":512,"briefTitle":513,"status":200,"phases":1230,"primaryCompletion":515,"completion":515,"start":516,"enrollment":517,"conditions":1231,"interventions":1232},[57],[519],[521,431,522],{"trials":1234,"activeCount":67},[],{"trials":1236,"activeCount":67},[],{"trials":1238,"activeCount":67},[],{"intervention":522,"totalTrials":63,"cells":1240},{"EARLY_PHASE1":1241,"PHASE1":1243,"PHASE2":1245,"PHASE3":1251,"PHASE4":1253,"NA":1255},{"trials":1242,"activeCount":67},[],{"trials":1244,"activeCount":67},[],{"trials":1246,"activeCount":67},[1247],{"nctId":512,"briefTitle":513,"status":200,"phases":1248,"primaryCompletion":515,"completion":515,"start":516,"enrollment":517,"conditions":1249,"interventions":1250},[57],[519],[521,431,522],{"trials":1252,"activeCount":67},[],{"trials":1254,"activeCount":67},[],{"trials":1256,"activeCount":67},[],{"intervention":1258,"totalTrials":63,"cells":1259},"Eicosapentaenoic acid free fatty acid",{"EARLY_PHASE1":1260,"PHASE1":1262,"PHASE2":1264,"PHASE3":1275,"PHASE4":1277,"NA":1279},{"trials":1261,"activeCount":67},[],{"trials":1263,"activeCount":67},[],{"trials":1265,"activeCount":67},[1266],{"nctId":1267,"briefTitle":1268,"status":166,"phases":1269,"primaryCompletion":1270,"completion":1270,"start":1271,"enrollment":1272,"conditions":1273,"interventions":1274},"NCT01070355","Eicosapentaenoic Acid (EPA) for Treatment of Colorectal Cancer Liver Metastases",[57],"2011-10","2010-04",88,[1117],[1258],{"trials":1276,"activeCount":67},[],{"trials":1278,"activeCount":67},[],{"trials":1280,"activeCount":67},[],{"intervention":162,"totalTrials":63,"cells":1282},{"EARLY_PHASE1":1283,"PHASE1":1285,"PHASE2":1287,"PHASE3":1293,"PHASE4":1295,"NA":1297},{"trials":1284,"activeCount":67},[],{"trials":1286,"activeCount":67},[],{"trials":1288,"activeCount":67},[1289],{"nctId":153,"briefTitle":154,"status":155,"phases":1290,"primaryCompletion":157,"completion":157,"start":157,"enrollment":67,"conditions":1291,"interventions":1292},[56,57],[159],[144,161,162],{"trials":1294,"activeCount":67},[],{"trials":1296,"activeCount":67},[],{"trials":1298,"activeCount":67},[],{"intervention":1300,"totalTrials":63,"cells":1301},"Lisinopril",{"EARLY_PHASE1":1302,"PHASE1":1304,"PHASE2":1306,"PHASE3":1317,"PHASE4":1319,"NA":1321},{"trials":1303,"activeCount":67},[],{"trials":1305,"activeCount":67},[],{"trials":1307,"activeCount":67},[1308],{"nctId":1309,"briefTitle":1310,"status":200,"phases":1311,"primaryCompletion":1312,"completion":1312,"start":1312,"enrollment":1313,"conditions":1314,"interventions":1316},"NCT03422705","A Pilot Study: Preventing Adverse Remodelling Following Pacemaker Implantation",[57],"2022-12-01",75,[1315],"Pacemakers, Heart Failure",[1300],{"trials":1318,"activeCount":67},[],{"trials":1320,"activeCount":67},[],{"trials":1322,"activeCount":67},[],{"intervention":1324,"totalTrials":63,"cells":1325},"Vorinostat Velcade Dexamethasone",{"EARLY_PHASE1":1326,"PHASE1":1328,"PHASE2":1330,"PHASE3":1342,"PHASE4":1344,"NA":1346},{"trials":1327,"activeCount":67},[],{"trials":1329,"activeCount":67},[],{"trials":1331,"activeCount":67},[1332],{"nctId":1333,"briefTitle":1334,"status":166,"phases":1335,"primaryCompletion":1336,"completion":1337,"start":1338,"enrollment":1339,"conditions":1340,"interventions":1341},"NCT01720875","Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)",[57],"2015-08","2018-08-29","2013-08-09",16,[18],[1324],{"trials":1343,"activeCount":67},[],{"trials":1345,"activeCount":67},[],{"trials":1347,"activeCount":67},[],{"intervention":404,"totalTrials":63,"cells":1349},{"EARLY_PHASE1":1350,"PHASE1":1352,"PHASE2":1354,"PHASE3":1360,"PHASE4":1362,"NA":1364},{"trials":1351,"activeCount":67},[],{"trials":1353,"activeCount":67},[],{"trials":1355,"activeCount":67},[1356],{"nctId":394,"briefTitle":395,"status":166,"phases":1357,"primaryCompletion":397,"completion":397,"start":398,"enrollment":399,"conditions":1358,"interventions":1359},[57],[401],[403,385,404],{"trials":1361,"activeCount":67},[],{"trials":1363,"activeCount":67},[],{"trials":1365,"activeCount":67},[],{"intervention":1214,"totalTrials":63,"cells":1367},{"EARLY_PHASE1":1368,"PHASE1":1370,"PHASE2":1372,"PHASE3":1378,"PHASE4":1380,"NA":1382},{"trials":1369,"activeCount":67},[],{"trials":1371,"activeCount":67},[],{"trials":1373,"activeCount":67},[1374],{"nctId":1205,"briefTitle":1206,"status":155,"phases":1375,"primaryCompletion":1208,"completion":1208,"start":1209,"enrollment":67,"conditions":1376,"interventions":1377},[56,57],[1211,1212],[1184,1214],{"trials":1379,"activeCount":67},[],{"trials":1381,"activeCount":67},[],{"trials":1383,"activeCount":67},[],{"intervention":174,"totalTrials":63,"cells":1385},{"EARLY_PHASE1":1386,"PHASE1":1388,"PHASE2":1390,"PHASE3":1396,"PHASE4":1398,"NA":1400},{"trials":1387,"activeCount":67},[],{"trials":1389,"activeCount":67},[],{"trials":1391,"activeCount":67},[1392],{"nctId":164,"briefTitle":165,"status":166,"phases":1393,"primaryCompletion":168,"completion":169,"start":170,"enrollment":171,"conditions":1394,"interventions":1395},[57],[18],[174,144,175],{"trials":1397,"activeCount":67},[],{"trials":1399,"activeCount":67},[],{"trials":1401,"activeCount":67},[],{"intervention":1403,"totalTrials":63,"cells":1404},"Cefuroxime 4 hourly bolus",{"EARLY_PHASE1":1405,"PHASE1":1407,"PHASE2":1409,"PHASE3":1420,"PHASE4":1422,"NA":1424},{"trials":1406,"activeCount":67},[],{"trials":1408,"activeCount":67},[],{"trials":1410,"activeCount":67},[1411],{"nctId":1412,"briefTitle":1413,"status":166,"phases":1414,"primaryCompletion":1415,"completion":1415,"start":1336,"enrollment":1416,"conditions":1417,"interventions":1419},"NCT02445859","Continuous Antibiotic Prophylaxis in Colorectal Surgery",[57],"2017-05",90,[1418],"Surgical Site Infection",[1403],{"trials":1421,"activeCount":67},[],{"trials":1423,"activeCount":67},[],{"trials":1425,"activeCount":67},[],{"intervention":1427,"totalTrials":63,"cells":1428},"EMI-137",{"EARLY_PHASE1":1429,"PHASE1":1431,"PHASE2":1433,"PHASE3":1446,"PHASE4":1448,"NA":1450},{"trials":1430,"activeCount":67},[],{"trials":1432,"activeCount":67},[],{"trials":1434,"activeCount":67},[1435],{"nctId":1436,"briefTitle":1437,"status":166,"phases":1438,"primaryCompletion":1439,"completion":1440,"start":1441,"enrollment":9,"conditions":1442,"interventions":1445},"NCT03360461","EMI-137 in Laparoscopic Colonic Resections",[57],"2020-02-14","2020-03-14","2018-02-14",[1443,1444],"Colonic Cancer","Metastasis to Lymph Node",[1427],{"trials":1447,"activeCount":67},[],{"trials":1449,"activeCount":67},[],{"trials":1451,"activeCount":67},[],{"intervention":1453,"totalTrials":63,"cells":1454},"AZD4017",{"EARLY_PHASE1":1455,"PHASE1":1457,"PHASE2":1459,"PHASE3":1471,"PHASE4":1473,"NA":1475},{"trials":1456,"activeCount":67},[],{"trials":1458,"activeCount":67},[],{"trials":1460,"activeCount":67},[1461],{"nctId":1462,"briefTitle":1463,"status":166,"phases":1464,"primaryCompletion":1465,"completion":1466,"start":1467,"enrollment":1468,"conditions":1469,"interventions":1470},"NCT03313297","Glucocorticoids and Skin Healing in Diabetes (GC-SHealD)",[57],"2019-02-27","2019-03-13","2018-04-10",28,[260],[1453],{"trials":1472,"activeCount":67},[],{"trials":1474,"activeCount":67},[],{"trials":1476,"activeCount":67},[],{"intervention":195,"totalTrials":63,"cells":1478},{"EARLY_PHASE1":1479,"PHASE1":1481,"PHASE2":1483,"PHASE3":1489,"PHASE4":1491,"NA":1493},{"trials":1480,"activeCount":67},[],{"trials":1482,"activeCount":67},[],{"trials":1484,"activeCount":67},[1485],{"nctId":185,"briefTitle":186,"status":166,"phases":1486,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":1487,"interventions":1488},[57],[193],[195,144,196],{"trials":1490,"activeCount":67},[],{"trials":1492,"activeCount":67},[],{"trials":1494,"activeCount":67},[],{"intervention":196,"totalTrials":63,"cells":1496},{"EARLY_PHASE1":1497,"PHASE1":1499,"PHASE2":1501,"PHASE3":1507,"PHASE4":1509,"NA":1511},{"trials":1498,"activeCount":67},[],{"trials":1500,"activeCount":67},[],{"trials":1502,"activeCount":67},[1503],{"nctId":185,"briefTitle":186,"status":166,"phases":1504,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":1505,"interventions":1506},[57],[193],[195,144,196],{"trials":1508,"activeCount":67},[],{"trials":1510,"activeCount":67},[],{"trials":1512,"activeCount":67},[],{"intervention":208,"totalTrials":63,"cells":1514},{"EARLY_PHASE1":1515,"PHASE1":1517,"PHASE2":1519,"PHASE3":1525,"PHASE4":1527,"NA":1529},{"trials":1516,"activeCount":67},[],{"trials":1518,"activeCount":67},[],{"trials":1520,"activeCount":67},[1521],{"nctId":198,"briefTitle":199,"status":200,"phases":1522,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":1523,"interventions":1524},[57],[18],[144,208,161,209,175,210,211],{"trials":1526,"activeCount":67},[],{"trials":1528,"activeCount":67},[],{"trials":1530,"activeCount":67},[],{"intervention":209,"totalTrials":63,"cells":1532},{"EARLY_PHASE1":1533,"PHASE1":1535,"PHASE2":1537,"PHASE3":1543,"PHASE4":1545,"NA":1547},{"trials":1534,"activeCount":67},[],{"trials":1536,"activeCount":67},[],{"trials":1538,"activeCount":67},[1539],{"nctId":198,"briefTitle":199,"status":200,"phases":1540,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":1541,"interventions":1542},[57],[18],[144,208,161,209,175,210,211],{"trials":1544,"activeCount":67},[],{"trials":1546,"activeCount":67},[],{"trials":1548,"activeCount":67},[],{"intervention":210,"totalTrials":63,"cells":1550},{"EARLY_PHASE1":1551,"PHASE1":1553,"PHASE2":1555,"PHASE3":1561,"PHASE4":1563,"NA":1565},{"trials":1552,"activeCount":67},[],{"trials":1554,"activeCount":67},[],{"trials":1556,"activeCount":67},[1557],{"nctId":198,"briefTitle":199,"status":200,"phases":1558,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":1559,"interventions":1560},[57],[18],[144,208,161,209,175,210,211],{"trials":1562,"activeCount":67},[],{"trials":1564,"activeCount":67},[],{"trials":1566,"activeCount":67},[],{"intervention":211,"totalTrials":63,"cells":1568},{"EARLY_PHASE1":1569,"PHASE1":1571,"PHASE2":1573,"PHASE3":1579,"PHASE4":1581,"NA":1583},{"trials":1570,"activeCount":67},[],{"trials":1572,"activeCount":67},[],{"trials":1574,"activeCount":67},[1575],{"nctId":198,"briefTitle":199,"status":200,"phases":1576,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":1577,"interventions":1578},[57],[18],[144,208,161,209,175,210,211],{"trials":1580,"activeCount":67},[],{"trials":1582,"activeCount":67},[],{"trials":1584,"activeCount":67},[],{"intervention":1586,"totalTrials":63,"cells":1587},"Cefuroxime",{"EARLY_PHASE1":1588,"PHASE1":1590,"PHASE2":1592,"PHASE3":1605,"PHASE4":1607,"NA":1609},{"trials":1589,"activeCount":67},[],{"trials":1591,"activeCount":67},[],{"trials":1593,"activeCount":67},[1594],{"nctId":1595,"briefTitle":1596,"status":200,"phases":1597,"primaryCompletion":1598,"completion":1598,"start":1599,"enrollment":1600,"conditions":1601,"interventions":1604},"NCT05609240","Colo-Pro_2: Bolus-continuous Infusion Cefuroxime Prophylaxis for the Prevention of Infections After Colorectal Surgery",[57],"2025-05-01","2023-05-10",180,[1602,1603],"Antibiotic Prophylaxis","Colorectal Surgery",[1586],{"trials":1606,"activeCount":67},[],{"trials":1608,"activeCount":67},[],{"trials":1610,"activeCount":67},[],{"intervention":1612,"totalTrials":63,"cells":1613},"Orencia 125 MG Per 1 ML Prefilled Syringe",{"EARLY_PHASE1":1614,"PHASE1":1616,"PHASE2":1618,"PHASE3":1628,"PHASE4":1630,"NA":1632},{"trials":1615,"activeCount":67},[],{"trials":1617,"activeCount":67},[],{"trials":1619,"activeCount":67},[1620],{"nctId":1621,"briefTitle":1622,"status":503,"phases":1623,"primaryCompletion":1624,"completion":1624,"start":1625,"enrollment":24,"conditions":1626,"interventions":1627},"NCT04261023","Abatacept in Individuals Who aRe Considered At Risk of Developing Inflammatory Arthritis",[57],"2021-03-15","2020-02-24",[488],[1612],{"trials":1629,"activeCount":67},[],{"trials":1631,"activeCount":67},[],{"trials":1633,"activeCount":67},[],{"intervention":1635,"totalTrials":63,"cells":1636},"azacitidine",{"EARLY_PHASE1":1637,"PHASE1":1639,"PHASE2":1641,"PHASE3":1651,"PHASE4":1653,"NA":1655},{"trials":1638,"activeCount":67},[],{"trials":1640,"activeCount":67},[],{"trials":1642,"activeCount":67},[1643],{"nctId":1644,"briefTitle":1645,"status":166,"phases":1646,"primaryCompletion":664,"completion":447,"start":1647,"enrollment":517,"conditions":1648,"interventions":1650},"NCT01235117","Azacitidine in Treating Patients With Chronic Myelomonocytic Leukemia",[57],"2010-01",[1649],"Leukemia",[1635],{"trials":1652,"activeCount":67},[],{"trials":1654,"activeCount":67},[],{"trials":1656,"activeCount":67},[],{"intervention":1200,"totalTrials":63,"cells":1658},{"EARLY_PHASE1":1659,"PHASE1":1661,"PHASE2":1667,"PHASE3":1669,"PHASE4":1671,"NA":1673},{"trials":1660,"activeCount":67},[],{"trials":1662,"activeCount":67},[1663],{"nctId":1191,"briefTitle":1192,"status":200,"phases":1664,"primaryCompletion":1194,"completion":1195,"start":1196,"enrollment":1197,"conditions":1665,"interventions":1666},[56],[18],[1200,1201],{"trials":1668,"activeCount":67},[],{"trials":1670,"activeCount":67},[],{"trials":1672,"activeCount":67},[],{"trials":1674,"activeCount":67},[],{"intervention":1676,"totalTrials":534,"cells":1677},"Glucocorticoids",{"EARLY_PHASE1":1678,"PHASE1":1680,"PHASE2":1682,"PHASE3":1684,"PHASE4":1686,"NA":1688},{"trials":1679,"activeCount":67},[],{"trials":1681,"activeCount":67},[],{"trials":1683,"activeCount":67},[],{"trials":1685,"activeCount":67},[],{"trials":1687,"activeCount":67},[],{"trials":1689,"activeCount":67},[1690,1701],{"nctId":1691,"briefTitle":1692,"status":166,"phases":1693,"primaryCompletion":1694,"completion":1695,"start":1696,"enrollment":1697,"conditions":1698,"interventions":1700},"NCT03760562","The Risk of Hypertension Associated With Oral Glucocorticoids in Chronic Inflammatory Diseases",[],"2015-01-30","2015-09-30","1998-01-01",111804,[1699],"Hypertension",[1676],{"nctId":1702,"briefTitle":1703,"status":166,"phases":1704,"primaryCompletion":1694,"completion":1695,"start":1696,"enrollment":1697,"conditions":1705,"interventions":1708},"NCT03575247","The Risk of Adrenal Insufficiency and Cushing Syndrome Associated With Glucocorticoid Therapy in People With Chronic Inflammatory Diseases",[],[1706,1707],"Adrenal; Insufficiency Gluccorticoid-Induced","Cushing; Syndrome or Disease, Glucocorticoid-Induced",[1676],{"intervention":1710,"totalTrials":63,"cells":1711},"Ivabradine",{"EARLY_PHASE1":1712,"PHASE1":1714,"PHASE2":1716,"PHASE3":1718,"PHASE4":1720,"NA":1722},{"trials":1713,"activeCount":67},[],{"trials":1715,"activeCount":67},[],{"trials":1717,"activeCount":67},[],{"trials":1719,"activeCount":67},[],{"trials":1721,"activeCount":67},[],{"trials":1723,"activeCount":67},[1724],{"nctId":1725,"briefTitle":1726,"status":166,"phases":1727,"primaryCompletion":1728,"completion":1728,"start":1729,"enrollment":1730,"conditions":1731,"interventions":1734},"NCT02247245","The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients.",[60],"2015-09","2014-09",40,[15,1732,1733],"Atrial Fibrillation","Arrhythmia, Sinus",[1710],{"intervention":1736,"totalTrials":63,"cells":1737},"zoledronic acid",{"EARLY_PHASE1":1738,"PHASE1":1740,"PHASE2":1742,"PHASE3":1744,"PHASE4":1746,"NA":1748},{"trials":1739,"activeCount":67},[],{"trials":1741,"activeCount":67},[],{"trials":1743,"activeCount":67},[],{"trials":1745,"activeCount":67},[],{"trials":1747,"activeCount":67},[],{"trials":1749,"activeCount":67},[1750],{"nctId":1751,"briefTitle":1752,"status":503,"phases":1753,"start":1754,"enrollment":1755,"conditions":1756,"interventions":1762},"NCT00458796","Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone",[60],"2006-03",1500,[1757,1758,1759,1760,1761],"Breast Cancer","Hypercalcemia of Malignancy","Metastatic Cancer","Musculoskeletal Complications","Pain",[1736],{"intervention":1764,"totalTrials":63,"cells":1765},"Icosapent Ethyl Oral",{"EARLY_PHASE1":1766,"PHASE1":1768,"PHASE2":1770,"PHASE3":1772,"PHASE4":1774,"NA":1776},{"trials":1767,"activeCount":67},[],{"trials":1769,"activeCount":67},[],{"trials":1771,"activeCount":67},[],{"trials":1773,"activeCount":67},[],{"trials":1775,"activeCount":67},[],{"trials":1777,"activeCount":67},[1778],{"nctId":1779,"briefTitle":1780,"status":166,"phases":1781,"primaryCompletion":1782,"completion":1782,"start":1783,"enrollment":1784,"conditions":1785,"interventions":1787},"NCT04682665","Prebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver Metastases",[],"2024-07-31","2021-09-16",81,[1786],"Colon Cancer Liver Metastasis",[1764],{"intervention":1789,"totalTrials":63,"cells":1790},"Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD",{"EARLY_PHASE1":1791,"PHASE1":1793,"PHASE2":1795,"PHASE3":1797,"PHASE4":1799,"NA":1801},{"trials":1792,"activeCount":67},[],{"trials":1794,"activeCount":67},[],{"trials":1796,"activeCount":67},[],{"trials":1798,"activeCount":67},[],{"trials":1800,"activeCount":67},[],{"trials":1802,"activeCount":67},[1803],{"nctId":1804,"briefTitle":1805,"status":166,"phases":1806,"completion":1807,"start":1808,"enrollment":1809,"conditions":1810,"interventions":1812},"NCT00518479","Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression",[60],"2004-04","2003-09",42,[1699,1811],"Left Ventricular Hypertrophy",[1789,1813],"Valsartan 160mg OD; Moxonidine 400mcg OD",{"intervention":1813,"totalTrials":63,"cells":1815},{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1820,"PHASE3":1822,"PHASE4":1824,"NA":1826},{"trials":1817,"activeCount":67},[],{"trials":1819,"activeCount":67},[],{"trials":1821,"activeCount":67},[],{"trials":1823,"activeCount":67},[],{"trials":1825,"activeCount":67},[],{"trials":1827,"activeCount":67},[1828],{"nctId":1804,"briefTitle":1805,"status":166,"phases":1829,"completion":1807,"start":1808,"enrollment":1809,"conditions":1830,"interventions":1831},[60],[1699,1811],[1789,1813]]